EpiGenX Rounds Out Scientific Advisory Board with Nobel Laureate
(Business Wire)...and is a leading expert in the field of methylation, including identifying non-random and tumor-specific methylation patterns in human malignancies.......Dr Costello is a member of the Brain Tumor Research Center at UCSF and has had his work featured in editorials published in Nature Genetics,...- May 07 11:40 AM ET
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
Posted on: 05/07/2001
"Yahoo - EpiGenX Rounds Out Scientific Advisory Board with Nobel Laureate"
[ Latest Headlines
News Alerts ]
Monday May 7, 11:40 am Eastern Time
EpiGenX Rounds Out Scientific Advisory Board with Nobel Laureate
Dr. Yuan-Tseh Lee Joins Fellow Scientists on Biotechnology Company Advisory Board
SANTA BARBARA, Calif.--(BW HealthWire)--May 7, 2001--EpiGenX
Pharmaceuticals Inc., announced today that Dr. Yuan-Tseh Lee has
joined a distinguished advisory board which has been assembled to
guide the Company in the development of epigenetic-based diagnostics
and therapies for cancer and infectious disease. The Scientific
Advisory Board, composed of leading scientists in the biotechnology
and academic community, will be instrumental in accelerating the
development and commercialization of the company's technologies.
Dr. Yuan-Tseh Lee joins an elite group including Michael T.
Bowers, Ph.D., Professor of Chemistry and Thomas C. Bruice, Ph.D.,
Professor of Chemistry and Biochemistry from University of California,
Santa Barbara; Joseph F. Costello, Ph.D., on the faculty of University
of California, San Francisco, Department of Neurological Surgery;
Melvin Louis DePamphilis, Ph.D., Section Chief for the Eukaryotic DNA
Replication and Gene Expression unit of the Molecular Growth
Laboratory at the National Institute of Child Health and Human
Development; as well as Jeffrey L. Ebersole, Ph.D., Professor of Oral
Health Research and Director, Center for Oral Health Research, from
University of Kentucky, College of Dentistry and Arthur D. Riggs,
Ph.D., Associate Director of the Beckman Research Institute of the
City of Hope National Medical Center.
EpiGenX's Scientific Advisory Board now features expertise
covering cancer biology, infectious disease, bioorganic chemistry and
mass spectrometry technologies. Epigenetic strategies entail
developing the advanced understanding of gene regulation, and its
manipulation in order to fight disease, particularly cancer and
"We are extremely honored to have Dr. Lee join our advisory
board," commented Larry Bymaster, President and Chief Executive
Officer, EpiGenX. "He has unparalleled expertise in molecular beam
technology and we are pleased that he has agreed to provide counsel to
our team of scientists."
"Dr. Lee is universally recognized as a world leader in design and
use of customized state-of-the-art instrumentation for chemical
analysis," noted Alec Wodke, Director of Epigenomics, EpiGenX. "We
look forward to his guidance in defining the technology directions for
our High Throughput Epigenetic applications."
EpiGenX Scientific Advisory Board is now composed of:
Michael T. Bowers, Ph.D., a Professor of Chemistry at UCSB, and
one of the world's leading scientists in the field of mass
spectrometry has served for over 10 years as, Editor,
International Journal of Mass Spectrometry and Ion Processes and
serves as Associate Editor Journal of the American Chemical
Society. Dr. Bowers his Ph.D. in 1966 from the University of
Illinois. His Awards include: Nobel Laureate Signature Award of
the American Chemical Society (1988); American Chemical Society
Award for Outstanding Achievement in Mass Spectrometry (1996);
Guggenheim Fellowship (1994); and UCSB Faculty Research Lecturer(1994). He is a Fellow of the American Physical Society and of
the American Association for the Advancement of Science.
Thomas C. Bruice, Ph.D., a Professor of Chemistry and
Biochemistry at UCSB, was listed among the world's 50 most cited
chemists for the period from 1984 to 1991. He has been elected a
Member of the National Academy of Sciences (1974), a Fellow of
the American Academy of Arts and Sciences and a Fellow of the
AAAS (1989) as well as the Royal Society of Chemistry. His awards
include: NIH Career Development (1979); Lifetime Investigator and
MERIT Awards; Guggenheim Fellow (1979); UCSB Faculty Research
Award (1970); American Chemical Society Arthur C. Cope Scholar
Award (1987), Richard C. Tolman Medal (1979), Repligan Medal in
Biochemistry (1987), Alfred Bader Medal in Bioorganic and
Bioinorganic Chemistry (1988), and the James Flack Norris Award(1996) in physical organic chemistry.
Joseph F. Costello, Ph.D., serves on the faculty at University of
California, San Francisco, Department of Neurological Surgery,
and is a leading expert in the field of methylation, including
identifying non-random and tumor-specific methylation patterns in
human malignancies. His awards include the James S. McDonnell
Foundation 21st Century Scientist Award. Dr Costello is a member
of the Brain Tumor Research Center at UCSF and has had his work
featured in editorials published in Nature Genetics, Science, The
Scientist and Wired Magazine. He serves as an ad hoc reviewer for
Nature Genetics, Proceedings of the National Academy of Science,
Cancer Research, and Genes Chromosomes & Cancer.
Melvin Louis DePamphilis, Ph.D., is the Section Chief for the
Eukaryotic DNA Replication and Gene Expression unit of the
Molecular Growth Laboratory at the National Institute of Child
Health and Human Development, Bethesda, MD. He previously served
as a Laboratory Head and Full Member of the Roche Institute of
Molecular Biology, an Adjunct Professor in the Department of
Biological Sciences at Columbia University, and a Professor in
the Department of Biological Chemistry at Harvard Medical School.
Dr. DePamphilis is one of the country's leading experts in the
initiation of DNA replication in mammalian chromosomes; gene
expression at the beginning of mammalian development. He
currently serves on the editorial board of the following
journals: Molecular Reproduction and Development, Molecular
Biology Reports, Gene Therapy & Molecular Biology, Cell Structure
and Function and Molecular and Cellular Biology.
Jeffrey L. Ebersole, Ph.D., is Professor of Oral Health Research
and Director, Center for Oral Health Research, at University of
Kentucky, College of Dentistry. Earlier in his career, he was
Professor of Periodontics and Microbiology at The University of
Texas Health Center and, in the mid-1980's, Associate Clinical
Professor of Oral Biology and Pathophysiology at the Harvard
School of Dental Medicine. Dr. Ebersole's research area is B cell
biology and antibodies in secretory immunity and periodontal
immunobiology. He has had NIH funding for over 25 years. His
primary research emphasis is in the development, specificity and
functional abilities of antibodies in the oral cavity.
Yuan-Tseh Lee, Ph.D., a Nobel laureate in chemistry in 1986, is
the current President of Academia Sinica, the highest research
institute in Taiwan. In 1986, Lee shared the Nobel Prize in
Chemistry with Dudley R. Herschbach and John C. Polanyi for
helping to apply the technology and theory of physics to
chemistry. In his research, Lee extended Herschbach's "crossed
molecular beam technique" to analyze larger and more complex
molecules. Dr. Lee received his doctorate from the University of
California at Berkeley in 1965. His world-leading laboratory now
contains seven very sophisticated molecular beam apparati, which
were specially designed to pursue problems, associated with
reaction dynamics, photochemical processes, and molecular
spectroscopy. His awards include: Alfred P. Sloan Fellow (1969 -
1971); Fellow, American Academy of Arts and Science (1975);
Fellow, American Physical Society, (1976); John Simon Guggenheim
Fellow (1976 - 1977); Member, National Academy of Sciences(1979); Member, Academia Sinica, Taiwan, China (1980); Ernest O.
Lawrence Award, U.S. Department of Energy (1981); Peter Debye
Award of Physical Chemistry, American Chemical Society (1986) and
the National Medal of Science in 1986.
Arthur D. Riggs, Ph.D., a noted molecular biologist, serves as the
Chair, Division of Biology, and Associate Director of the Beckman
Research Institute of the City of Hope National Medical Center,
which has been designated a Comprehensive Cancer Center by NCI.
Dr. Riggs' was one of the scientific founders of Genentech. He is
a pioneer in developing an understanding of how methylation acts
as an epigenetic control. Currently he is studying X chromosome
inactivation and the biological roles of DNA methylation. Dr.
Riggs' scientific achievements span three decades at City of Hope.
EpiGenX has accepted invitations to make presentations at two
industry conferences this month. The company will be presenting at the
Innovative Drug Development Conference in New York on May 8th and the
C21 Biotech Convergence Conference in Monterey Bay, California on May
EpiGenX Pharmaceuticals is pioneering the development of
epigenetic-based diagnostics and therapies tailored to the needs of
individual patients. Epigenetic strategies entail developing the
advanced understanding of gene regulation, and its manipulation in
order to fight disease, particularly cancer and infections. The
company's technology platforms all involve DNA methylation. EpiGenX
has three commercialization pathways. Its drug discovery tools,
EpiHiTS(TM) Technology include a suite of high-throughput assays for
the rapid discovery of new epigenetic-based drugs. The company is
developing novel and safe therapeutics to fight cancer and infectious
diseases through epigenetic mechanisms. EpiGenX is also developing a
suite of high-throughput diagnostic and epigenomics technologies to
generate information on the activity and inactivity of genes in
relation to various diseases. EpiGenX Pharmaceuticals, Inc., is
located in Santa Barbara, CA. For more information, call 805-964-4486
or log on to http://www.epigenx.com
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 (the
"Act"). In particular, when used in the preceding discussion, the
words "plan," "confident that," "believe," "expect," "intend to" and
similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are
subject to the safe harbor created by the Act. Such statements are
subject to certain risks and uncertainties, and actual results could
differ materially from those expressed in any forward-looking
statements. Such risks and uncertainties include, but are not limited
to, market conditions, competitive factors, the ability to
successfully complete additional financings and other risks.
EpiGenX Pharmaceuticals, Inc.
Mark Wilkinson, 805/964-4486
Larry O. Bymaster, 805/964-4486
Ken Richards, 805/964-4486
Email this story - Most-emailed articles - Most-viewed articles
Copyright © 2001 Yahoo! Inc. All rights reserved.
Terms of Service
Copyright © 2001 Business
All rights reserved.
All the news releases provided by Business Wire are
Any forms of copying other than an individual user's
without express written permission is prohibited.
Further distribution of these materials is strictly
forbidden, including but
not limited to, posting, emailing, faxing, archiving
in a public database,
redistributing via a computer network or in a printed
Questions or Comments?
Click HERE to return to brain tumor news headlines